• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

No differences in the risk of hepatocellular carcinoma from using direct-acting antiviral agents or interferon in patients with chronic hepatitis C: A meta-analysis.

作者信息

Yang Xueying, Wang Nan, Li Si, Gu Yanan, Wang Zhen, Yang Dong

机构信息

College of Laboratory Medicine, Dalian Medical University, Dalian, China.

Department of Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.

出版信息

Clin Res Hepatol Gastroenterol. 2022 Dec;46(10):102001. doi: 10.1016/j.clinre.2022.102001. Epub 2022 Aug 12.

DOI:10.1016/j.clinre.2022.102001
PMID:35970428
Abstract
摘要

相似文献

1
No differences in the risk of hepatocellular carcinoma from using direct-acting antiviral agents or interferon in patients with chronic hepatitis C: A meta-analysis.
Clin Res Hepatol Gastroenterol. 2022 Dec;46(10):102001. doi: 10.1016/j.clinre.2022.102001. Epub 2022 Aug 12.
2
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C?干扰素疗法能否预防慢性丙型肝炎患者发生肝细胞癌？
Gastroenterology. 1999 Sep;117(3):738-9. doi: 10.1016/s0016-5085(99)70471-3.
3
Current status of antiviral therapy for chronic hepatitis C.慢性丙型肝炎抗病毒治疗的现状
Adv Exp Med Biol. 1999;458:29-37. doi: 10.1007/978-1-4615-4743-3_4.
4
End of the story: direct-acting antiviral agents are not associated with recurrence of hepatocellular carcinoma.故事的结局：直接抗病毒药物与肝细胞癌复发无关。
Gut. 2022 Mar;71(3):454-456. doi: 10.1136/gutjnl-2021-324288. Epub 2021 Mar 30.
5
The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma.
J Formos Med Assoc. 2021 Apr;120(4):1160. doi: 10.1016/j.jfma.2020.11.012. Epub 2020 Dec 5.
6
Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy.无症状丙型肝炎病毒感染患者的自然病程及干扰素治疗后的肝细胞癌
Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S89-91. doi: 10.1016/s1542-3565(05)00701-9.
7
[Impression of direct-acting antiviral agents in the treatment of recurrent hepatocellular carcinoma related to chronic hepatitis C].
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):179-183. doi: 10.3760/cma.j.issn.1007-3418.2018.03.005.
8
Response to letter to the editor "The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma".对致编辑信《直接抗病毒药物清除丙型肝炎病毒后细胞因子变化对肝细胞癌风险的影响》的回复
J Formos Med Assoc. 2021 Apr;120(4):1161-1164. doi: 10.1016/j.jfma.2020.12.016. Epub 2020 Dec 24.
9
Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.直接作用抗病毒药物对 HCV 相关 HCC 早期复发的影响：与基于干扰素的治疗比较。
J Hepatol. 2019 Jan;70(1):78-86. doi: 10.1016/j.jhep.2018.09.029. Epub 2018 Oct 16.
10
Hepatocellular carcinoma associated with direct-acting antiviral therapy for hepatitis C virus: A report of two cases.
Rev Gastroenterol Mex (Engl Ed). 2021 Apr-Jun;86(2):197-199. doi: 10.1016/j.rgmx.2020.04.008. Epub 2020 Nov 11.